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Abstract
Background: Practitioners need brief instruments to monitor outcomes in both treatment of drugs and alcohol addiction because they are useful to guide 
decision making in a short time. Objectives: This study aims to develop a brief questionnaire, based on Client Evaluation of Self and Treatment, to evaluate 
the treatment effectiveness in drug and alcohol addiction treatment settings. Methods: A cross-sectional study using a convenience sample (N = 608) recruited 
from Division for Intervention on Addictive Behaviours and Dependencies (DICAD – ARS North). Results: The results show a new four-factor solution that 
accounted for 54.4% of the total variance and that provides the best fit to the data (c2/df = 1.72, CFI = .94, GFI = .91, RMSEA = .048 [.040-.057]; prmsea = 
.623). It also revealed a high internal consistency (a = .82). It was found a significant negative correlation (r = - .52, p < .01) between the final version of the 
instrument and a self report measure of psychopathology symptoms. Discussion: This brief questionnaire, with good psychometric properties, can be useful 
to provide a viable and rapid feedback of treatment outcomes. Further studies should be performed to continue the evaluation of the reliability of this measure. 
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Introduction
There have been significant changes in addiction treatment over the 
past three decades, where has been a significant movement from 
inpatient to outpatient programs. However, while treatment pro-
grams have changed over time, monitoring the effectiveness during 
the implementation of these programs has been little explored both 
by researchers and practitioners1. There are two underlying main 
approaches to conceptualize the treatment effectiveness. One is the 
rehabilitation-oriented model is the traditional paradigm where the 
method used to evaluate the effectiveness of addiction treatment is 
based on post-treatment follow-up outcomes, assuming that benefits 
were attained during treatment, and positive changes have occurred 
by the end of the treatment, and it is expected sustained abstinence 
at the time of follow-up2. 
This method has been used in the case of residential treatment, 
where drugs are not available in the treatment setting, and the ef-
fectiveness outcome is evaluated for a substantial follow-up period of 
time. However, the limitation of this method is the excessive attention 
to the sustained and complete recovery from a substance use as cri-
terion of treatment effectiveness. According to White3 the problem is 
that “groups like Narcotics Anonymous (NA) have defined recovery 
in terms of abstinence from drug use, but addiction scientists have 
generally defined recovery from illicit drug dependence in terms 
of problem resolution rather than absence of drug use”. Thus, this 
conceptualization “would allow measuring levels of outcomes over 
time and answer questions about the viability of particular problem-
resolution strategies for particular populations”3. In addition, the 
pos-treatment follow-up method has other several limitations. The 
evaluations are usually conducted by an external researcher from 
the treatment team2, who do not measured patient changes during 
treatment. When participants are not located or refuse to participate 
at follow-up evaluations, the internal and external validity of the col-
lected data could be compromised due to the characteristics of those 
participants who drop out (e.g., involved in antisocial and criminal 
behaviors)4. Finally, many complex ethical issues arise from the 
follow-up evaluations, in part, due to the assertive methods required 
to generate high follow-up rates5. 
Other approach that has been suggested by researchers is the 
alternative method of evaluating the treatment effectiveness based 
on the monitoring method instead of follow-up results. This new 
conceptualization was emerged from two changes, namely the change 
of the health-care delivery system that moved from residential care 
to outpatient setting, where nowadays practitioner’s need for more 
economical, rapid and clinically relevant information to guide de-
cision making, and the transition of the recovery definition from 
medicalized term to a problem-solving process, and a psychosocial 
perspective2,3. The proposal called “concurrent recovery monitor-
ing” (CRM)2 could be described as a brief and repeated evaluations, 
relatively easy to collect, concurrent with treatment to monitor and 
assist patient change, toward clinical and social outcomes, and more 
relevant and in time information to guide the decision making in 
a more effective way2. For instance, clinical decisions about which 
specific treatments are more suitable according to the different pat-
terns of drug or alcohol use and the different characteristics of drug 
users6. Monitoring can also optimize the results of treatment7 and 
monitor the need and the readiness for change in programs and 
organizational factors8 and contribute to retention in treatment9. 
Further, the monitoring method can overcome the ethical problems 
of complex and large assessments, including the burden of time and 
efforts to generate high follow-up rates5. However, the practitioners 
need economical, rapid and clinical reliable methods to guide deci-
sion making in a short time period without compromising the patient 
attendance and participation in treatment. Complex or lengthy as-
sessment measures may also lead to staff noncompliance10. On the 
other hand, the monitoring system can be burdensome for clinical 
staff in cases of large time-consuming intake, weekly and follow-up 
assessments, and can compromise the quality of data through a 
monitoring system11. The solution appears to be the use of self-report 
questionnaires that took a short-time to be completed, not requiring 
the attendance of the staff member in training program, as in the case 
of interviews, and are well appropriate to systems of care10. 
Machado et al.1 conducted a study with individuals undergoing 
dependence treatment, where they created a software that allows 
building a database for monitoring the intervention efficacy in clini-
cal practice. For that, the authors used the following instruments: 
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(1) Drug Abuse Screening Test – Portuguese version (DAST) – a 
dichotomous 20-item scale to assess the severity level of consump-
tion. It evaluates the consequences related to consumption during the 
last 12 months such as physical and psychological symptoms, social 
and relational aspects, among others; (2) Outcome Questionnaire 
– Portuguese version (Q-45), a 45-item questionnaire that provides 
a reliable assessment of various aspects of the adjustment level and 
psychosocial disturbance of individuals; (3) The Inventory of Drug-
Taking Situations – Portuguese version (IDTS) – an instrument 
consisting of 50 items that describes potential drug use situations 
over the past year; it allows to recognize problematic situations and 
anticipate risk situations; (4) Consumer Satisfaction Questionnaire 
– Portuguese version (CSQ-8), an 8-item instrument to explore the 
degree of patient satisfaction regarding to treatments and services 
received and their impact on the patient’s life. This study brings a 
clear progress in terms of research in this area in Portugal. 
However, the administration of this wide array of assessment 
tools leads to a final database of about 123 items, making it difficult 
to apply on a regular basis in the clinical setting. On the other hand, 
if we choose not to apply the same instruments in all stages of evalu-
ation/monitoring we are not able to compare results of the various 
moments of administration, compromising the effective therapy 
evolution of individual consumers during their treatment.
There are other instruments available to monitor the effectiveness 
of treatment programs. Marsden et al.12 validated, for the European 
context, the Treatment Perceptions Questionnaire (TPQ). They also 
validated the Maudsley Addiction Profile (MAP), which adds some 
of the most relevant performance indicators in the evaluation of 
treatment outcomes. Notwithstanding, other important indicators of 
effectiveness (including the therapeutic relationship, the involvement 
or active participation in treatment, the social support network7,13-15, 
psychopathological symptoms, negative affects, or treatment orienta-
tion16-19 are missing in this questionnaire. 
Recently, studies conducted by Joe et al.7 and Simpson14 validated 
the Texas Christian University (TCU) Client Evaluation of Self and 
Treatment (CEST) a multidimensional instrument covering the 
main indicators of effectiveness of drug and dependence treatments 
that can and should be administered in repeated evaluations during 
the treatment process. The CEST was developed under the DATAR 
project, founded by the National Institute on Drug Abuse in 1993 
(Grant No.DA13093). The CEST has originally 130 items divided 
into 17 dimensions, taking 30 to 40 minutes to complete, which is 
its biggest limitation. 
So, we aimed to develop a short self-report measure, suitable for 
both inpatient and outpatient programs, encompassing evaluating 
of critical indicators of treatment effectiveness, using a problem-
solving and a psychosocial models. For that, we selected the pre-
vious Portuguese version20 of Texas Christian University – Client 
Evaluation of Self and Treatment – TCU – CEST. We also aimed 
to examine the validity of the new instrument comparing it with a 
psychopathology self-report measure, similarly to previous studies 
of the TCU-CEST7,14.
Methods
Participants
Six hundred and eight subjects were recruited from Intervention Ser-
vice on Addictive Behaviours and Substance Dependence (SICAD) 
– Regional Northern Section, in Portugal. The convenience sample 
was recruited from 3 main treatment settings: outpatient’s drug ad-
diction treatment (64%; n = 389); outpatient´s alcohol dependence 
treatment (14%; n = 85), and inpatient’s drug and alcohol dependence 
treatment (22%; n = 134).
We selected patients who were in treatment for, at least, one 
month. Furthermore, the researchers took into account changes 
resulting from psychopathology or recent consumption, which could 
interfere with the normal completion of the questionnaires
Procedures
After we obtained permission from the authors to use The 
TCU-CEST, SICAD and DICAD, then the study was submitted to 
the ethics committee of the Faculty of Psychology and Education 
Sciences (University of Porto), which approved the study. 
Researchers certified on addiction problems administered the 
instruments at the facilities of DICAD – North Regional Health 
Administration after the participants signed the free consent inform 
about the research. The confidentiality was ensured to all participants. 
Materials 
Socio-Demographic Questionnaire. This questionnaire included 
information about birth date, gender, age, birthplace, treatment 
program, treatment time and finally, the identification of primary 
substance of abuse.
Brief Symptoms Inventory (BSI)21,22. This is a reduced version of 
the Symptom Check List 90 Revised (SCL-90-R), a self-report inven-
tory consisting of 53 items. The participant must specify the degree 
to which each problem has affected them over the past week, on a 
Likert-type scale (1 – Never, 2 – Rarely, 3 – Sometimes, 4 – Often, 
5 – Very often). This inventory assesses psychopathological symptoms 
along nine basic dimensions (somatization, obsession-compulsion, 
interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, 
paranoid ideation and psychoticism) and three global indices (posi-
tive symptoms distress index – PSDI, global severity index – GSI, 
and positive symptom total – PST). In the present study, the various 
dimensions have an internal consistency ranging from moderate to 
high, with Cronbach’s alpha values between .70 to .85. The internal 
consistency of the overall BSI in this sample was .96.
Texas Christian University (TCU) – Client Evaluation of Self 
and Treatment (CEST)7,14. This instrument was developed as part 
of National Institute on Drug Abuse (NIDA). The original CEST is 
a 129-item self-rating instrument that includes 17 scales measuring 
patient functioning and treatment perceptions. Psychometric prop-
erties (including reliability and construct validity) of the scales are 
examined in Joe et al.7 and acceptable reliabilities (.70 or above) were 
generally reported, and construct validity was also demonstrated. The 
response format is a 7-point Likert scale (1 – I strongly disagree to 
7 – I strongly agree). We used the Portuguese version20 that included 
101 items that match the original 4 dimensions and 13 subscales, with 
reasonable to good internal consistency values (ranging from .54 to 
89), namely, (a) Treatment motivation dimension; (b) Psychological 
functioning dimension; (c) Social functioning dimension; and (d) 
Treatment engagement dimension
Statistic analysis
We used the Statistical Package for Social Sciences – SPSS (SPSS Inc., 
Chicago, IL, version 19.0) to perform the analyses. Concerning the 
psychometric sensitivity of the items, we found a high kurtosis (|ku| 
> 7) for item 62 and a high skewness (|sk| > 2) for items 8, 15, 26, 54, 
57, 62, 79, 104 and 12723. Without these items, we sought to establish 
the factor validity of the questionnaire through the Exploratory Fac-
tor Analysis (EFA), using the sample of 296 patients in treatment. In 
conducting the EFA, we used for factor extraction the principal axis 
factoring method and oblimin rotation with Kaiser normalization. 
Following the recommendations of Dziuban and Shirkey24, before 
the analysis, we explored the psychometric adequacy of the items. 
Next, we performed a confirmatory factor analysis through AMOS 
software. We also screened for major violations of normality, taking 
into account the absolute values of kurtosis (ku < 7) and skewness 
(sk < 2)23. The hypothesized model obtained through the EFA was 
evaluated using indices and respective values for an acceptable fit25: 
c2/df < 526 Comparative Fit Index – CFI > 0.90; Goodness Fit Index 
- GFI > 0.9027 Standardized Root Mean Square Residual – SRMR < 
0.1028, and Root Mean Square Error of Approximation – RMSEA 
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< 0.0826. A 90% confidence interval (Low90 and Hi90) was used to 
assess the precision of the RMSEA estimate29. We also considered p 
Close Fit – prmsea > 0.5029. 
Results
Regarding the sample, participants from outpatient´s drug addiction 
treatment included mainly men (89.4%), with ages ranging from 18 
to 61 (M = 39.7; SD = 7.8). The psychoactive substance reported as 
the primary drug of abuse prior to treatment was heroin for 58% of 
the sample, followed by poly-consumption (19.8%), cocaine (19.3%), 
hashish (2.1%) and replacement psychotherapeutic drugs – metha-
done/Subutex – for 0.3% of this sample. The mean duration of treat-
ment at the time of questionnaire administration was 40.61 months 
(SD = 40.9). The sample collected in outpatient’s alcohol dependence 
treatment included mostly men (82.4%), with ages ranging from 28 to 
73, (M = 47.3; SD = 9.4). The psychoactive substance reported as the 
primary drug of abuse prior to treatment was alcohol for 100% of the 
sample. The mean duration of treatment at the time of questionnaire 
administration was 32.1 months (SD = 39.9). Finally, the inpatient’s 
drug and alcohol dependence treatment sample included mainly 
men (90.1%), with ages ranging from 18 to 60 (M = 39.7; SD = 8.5). 
The psychoactive substance reported as the primary drug of abuse 
prior to treatment was alcohol for 56.4% of the sample, followed by 
heroine (18.8%), cocaine (9.8%), psychotherapeutic drugs – metha-
done/Subutex (9%), poly-consumption (4.6%), and other unspecified 
psychotherapeutic drugs (1.5%). The mean duration of treatment at 
the time of questionnaire administration was 2.6 months (SD = 8.9). 
Further, the total sample of 608 participants was randomly divided 
into two subsamples (N = 296 and N = 312) to properly perform the 
exploratory and confirmatory factor analyses.
Exploratory factor analysis
Bartlett’s Test of Sphericity was significant at p = .000, indicating a 
good correlation between the variables and the adequacy of the EFA 
to this scale. The Kaiser-Meyer-Olkin index was higher than the rec-
ommended value of .50 (KMO = .822). This last value showed us that 
the results obtained can be considered good according to Marôco30 
and Pestana and Gageiro31. Communality coefficients (h2 > .40) were 
also taken into account to assess the psychometric qualities of the 
instruments32. Nevertheless, we chose to keep the items with com-
munalities above .30 if they are theoretically justified. According to 
Cattell’s scree plot graphic31, there are four to six main factors. We ran 
EFA, establishing 4 factors because the theoretical model of the origi-
nal version also showed 4 overall factors7. The four-factor solution 
accounted for 29.9% of the total variance. However, some items had 
low communality values (h2 < .40). In this process, we eliminated the 
items with poor results (h2 < .40 if they are not theoretically justified) 
and ran the EFA repeatedly until we found a final model in which all 
items showed adequate results (Table 1). In this four-factor solution 
all items presented communality values above .35 and factor loadings 
ranging between .49 and .90 (Table 1). The final EFA revealed a new 
four-factor solution that accounted for 54.4% of the total variance. 
We renamed some of the subscales since there is a new combination 
of items: Therapeutic involvement (26.6%); Negative affects (12.4%); 
Social support (9.2%); and Peer support (6.2%). 
Table 1. Final Exploratory Factor Analysis: communalities and factor loading by item (N = 296)
Component
h2 1 2 3 4
84. [Your counselor respects your opinions] .562 .783 .021 -.036 -.145
63. [Your counselor helps you develop confidence in yourself] .654 .780 .029 .067 .015
30. [You are satisfied with this program] .594 .761 -.020 -.019 .057
80. [The staff here is good at doing its job] .576 .756 -.071 -.113 .102
43. [Your counselor is sensitive to your problems] .537 .745 -.048 -.142 .086
21. [You are motivated by your counselor] .547 .739 .050 .046 -.085
2. [You trust your counselor] .526 .734 .040 .028 -.105
38. [Your counselor recognizes the progress you make in treatment] .524 .691 -.024 .057 .031
20. [This program is organized] .480 .644 .039 .032 .124
115. [You have a good personal counseling at this program] .423 .625 -.090 .018 .017
67. [You have made progress in understanding your behavior] .371 .493 .059 .219 .015
105. [You feel nervous] .623 .046 .777 -.010 -.105
36. [You feel a lot of anger inside you] .554 -.037 .732 -.049 .144
70. [You feel anxious] .484 -.053 .694 .027 .056
92. [You get mad easily] .470 -.026 .676 .104 -.092
41. [You have a hot temper] .503 .046 .657 .270 -.182
90. [You worry or brood a lot] .425 .052 .644 -.034 .143
74. [You feel sad] .490 -.072 .589 -.289 .011
76. [You feel extra tired] .343 -.028 .501 -.244 .001
95. [You have people close to you who help you develop confidence in yourself] .722 .050 .036 .831 .009
64. [You have people close to you who understand your situation and problems] .636 -.040 -.074 .794 .031
107. [You have people close to you who respect your efforts in this program] .725 .120 .013 .786 .059
18. [You have people close to you who help you stay away from drugs/alcohol] .479 .004 .014 .694 -.008
29. [You have people close to you who can always be trusted] .470 -.061 -.012 .686 .081
77. [You have improved your personal relationships with other people] .425 .070 -.043 .604 .053
58. [Other clients at this program care about your situation and problems] .801 -.015 .032 .022 .895
72. [Other clients at this program are helpful to you] .777 -.017 -.005 .072 .868
99. [You have developed positive trusting friendships while at this program] .518 .215 .024 .212 .546
Note: Boldface indicates the items belonging to the factor.
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Confirmatory factor analysis
All items were distributed within the normality range (|ku| < 4.601 
and |sk| < 1.899). Sixteen outliers were found using Mahalanobis 
squared distance (p1 and p2 < 0.00)25. Because the analysis of the 
model fit without outliers showed similar results, we decided not ex-
clude these cases from the analysis30. The model obtained by the EFA 
with 4 factors and 28 items was tested (Figure 1). The hypothesized 
model revealed a poor global fit (Table 2). However, we have ana-
lyzed modification indices and we proceeded to the change of paths 
only when if it made sense according to the theoretical premises: 
the regression values show us that items 20, 21 29, 43, 77 and 99 are 
repeatedly associated with items outside the factor they belong to, 
thus revealing their multidimensionality (see contents of the items 
in attachment file). Consequently, we decided to remove these items 
from the model. The modification indices also suggested covariance 
between the errors of items 74 ↔ 76, 41 ↔ 92 (see contents of the 
items in attachment file). Following these changes, we obtained a 
short version with 22 items. For this new version, results allow us 
to classify the model (Figure 2) as a whole as acceptable/good (c2/
df = 1.724, CFI = .941, GFI = .907, SRMR = .155, RMSEA = .048 
[.040 - .057]; prmsea = .623)33.
Reliability (Cronbach’s alpha)
According to the recommended default value of > .7031, the analyses 
of the values obtained showed us that the Therapeutic involvement, 
Negative affects, Social support and Peer support subcales of new 
version (22 items) have, respectively, Cronbach’s alpha values of 
.87, .82, .85 e .83. The global instrument has also a high internal 
consistency (a = .82). 
Convergent validity
Correlation coefficients are reported in tables 3 e 4. The results 
show that there is a positive and significant association between all 
subscales and the total score of the new instrument (ranging from 
r = .45 to r = .68, p < .01), except for the subscale Negative affects, 
whose association is significant, but negative, as expected by theory 
(r = - .74 , p < .01 ) (Table 3). We also found a significant negative 
association between the total score of the new instrument and the 
General Symptom Index of BSI (BSI-GSI) (r = - .52, p < .01), as well 
as between the total score of the new instrument and all BSI subscales 
(p < .01) (Table 4). In turn, the subscales Negative affects and Social 
support are significantly associated not only with the BSI-GSI (r = 
.59, p < .01 and r = - .26, p < .01), but with all dimensions of the BSI 
as well (p < .01) (Table 4). 
Discussion
The main goal of this article was to develop a brief questionnaire 
of treatment monitoring, suitable for both inpatient and outpatient 
programs, to assess critical indicators of treatment effectiveness in 
a short time period. The choice of the TCU-CEST instrument was 
based upon four basic criteria: (a) adequate psychometric pro-
prieties found in the original instrument, (b) several TCU-CEST 
subscales have been applied to a variety of dependence treatment 
programs, (c) wide assessment of several efficacy indicators, and 
(d) confirmed usefulness in clinical practice and in the present 
changes in treatment programs7,14. We started from a theoreti-
cal model of this original CEST7,14, and the Portuguese version 
of Moura et al.20, to found a brief questionnaire to evaluate the 
treatment effectiveness of substance abuse, using both inpatient 
and outpatient samples, and subsequently EFA and CFA analyses. 
According to our purposes, we found a different factor structure 
when compared to the original instrument, with a four-factor 
model from EFA analyses. These four factors also showed adequate 
internal reliability. The adequacy of this structure to a different 
sample was confirmed through the CFA. Nevertheless, a model 
re-specification was necessary. We believe that the statistical model 
allowed us to find a different version due to the inclusion of patient 
characteristics of different treatment settings, compared to the 
original instrument. 
Despite this, our final model covers the main treatment effec-
tiveness areas pointed out in literature. The first factor, identified as 
Therapeutic involvement dimension, includes items intended to mea-
sure treatment engagement, treatment satisfaction and counseling 
rapport. The second factor, identified as Negative affects dimension, 
includes items to measure the psychological functioning in terms of 
depression, hostility and anxiety. Third and fourth factors, originally 
identified as Social and Peer support scales, respectively, seek to 
measure social and contextual factors that also affect recovery process 
dynamics7. Former instruments are extensive, which takes a long 
time to be completed and analyzed, like the software developed by 
Machado et al.1, where several instruments were combined resulting 
in a 126-items instruments. Besides, these instruments don’t include 
some important constructs stressed by literature such as social and 
peer support network7,14, the therapeutic relationship, the involve-
ment or active participation in treatment13-15, psychopathological 
symptoms or negative affects16-19. 
In this way, when compared with others instruments, this new 
short-form presented here is a proper response since: (a) it is suitable 
for both inpatient and outpatient programs; (b) encompasses few, 
but critical indicators of treatment, using a problem-solving and a 
psychosocial models; (c) takes short time to be completed; and (d) 
allows building a database for the monitoring of intervention efficacy 
available in clinical practice.
Our second aim was to investigate the convergent validity of 
the brief instrument. There were significant associations of most of 
these subscales with each other and with the total score, suggesting 
the concordance of the subscales for the evaluation of different as-
pects of a common construct. Furthermore, we concluded that this 
study showed a significant correlation between the brief instrument 
and the BSI. The majority of the brief instrument subscales (75%) 
were significantly associated with at least five or more dimensions 
of the BSI, and half of the brief instrument subscales (50%) were 
significantly associated with all dimensions of the BSI and total 
score. Furthermore, the global score of the brief instrument was also 
significantly associated with all dimensions of the BSI and total score. 
Exceptionally, the scale Peer support was not significantly associated 
with any of the BSI’s dimensions. Despite of the low probability that 
this subscale had any relation with psychopathological symptoms, 
it was significantly associated with the other subscales of the new 
instrument, as well as with the total score, being reasonable to keep 
this scale in the final instrument.
These results are consistent with the literature stating that 
psychopathology34,35 and comorbidity36,37 are very commons in this 
population. Psychopathology was one of the best predictors of the 
effectiveness of treatment programs35, increasing the likelihood of 
treatment failure34,35. Therefore, if this brief instrument is strongly 
and significantly associated with the BSI (a predictor of the effec-
tiveness of treatment programs), these data seem to reinforce the 
potential of this version in the estimation of treatment efficacy. 
Considering the practical implications, this new brief questionnaire, 
with adequate psychometric properties, can be useful to provide 
a viable and rapid feedback instrument for counselors, treatment 
programs and policy makers, covering some of the main and most 
relevant areas related to the monitoring of drugs and alcohol treat-
ment programs3,5,7-9. Furthermore, this practice can also enable the 
adjustment of the interventions according to the users’ needs and 
comorbidities7,9,14,20. We also suggest that this instrument should be 
part of the daily work in clinical practice in Portugal. Thus, more 
studies may be conducted in context: measuring the treatment 
effectiveness and warning of the need for effective changes in the 
recovery process.
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Figure 1. Model 1 – 4 correlated factors and 28 items.
CFA
X2 (344) = 774,957; p= .000; X2df = 2,253
CFI = .877; GFI = .846;
RMSEA = .063; P (rmsea ≤ 0.05) = .000
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Figure 2. Model 2 – 4 correlated factors and 22 items.
CFA
X2 (201) = 346,461; p = .000; X2df = 1,724;
CFI = .941; GFI = .907;
RMSEA = .048; P (rmsea ≤ 0.05) = 623
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Table 2. Confirmatory Factor Analysis: global adjustment indices (N = 312)
c2 df c2/df CFI GFI SRMR RMSEA p rmsea
Model 1: 4 correlated factors (with 28 items) 775* 344 2.253 .877 .846 .178 .063 [.058; .069] .000
Model 2: 4 correlated factors (with 22 items) 346* 201 1.724 .941 .907 .155 .048 [.040; .057] .623
* p < .001.
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Table 3. Correlation matrix of subscales
Global score Therapeutic involvement Social support Peer support
Global score 
Therapeutic involvement .569**
Social support .678** .494**
Peer support .454** .225** .285**
Negative affects -.736** -.034 -.181** -.065
**p < .01.
Table 4. Correlation matrix of brief questionnaire and BSI scales
Global score Therapeutic involvement Social Support Peer support Negative affects
BSI-GSI -.515** -.128** -.261** -.011 .592**
Somatization -.394** -.132** -.200** -.037 .424**
Obsession-compulsion -.345** -.061 -.184** .037 .420**
Interpersonal sensitivity -.329** -.047 -.161** .070 .427**
Depression -.515** -.179** -.313** -.053 .521**
Anxiety -.443** -.079 -.183** .025 .561**
Hostility -.493** -.146** -.219** -.035 .562**
Phobic anxiety -.231** -.027 -.134** .023 .284**
Paranoid ideation -.406** -.069 -.233** -.045 .458**
Psychoticism -.403** -.101* -.171** .017 .489**
** p < .01; * p < .05.
Limitations
First, these three major treatment settings are not necessarily rep-
resentative of all treatment programs for drug or alcohol addiction 
in Portugal. Second, this short version does not measure the same 
number of dimensions of treatment efficacy as the original version. 
Thus, we can conceive it only as an important complementary tool 
for this assessment. Finally, more studies should be conducted in 
Portugal with this short version to assess temporal validation of 
this instrument, and to observe correlations with others indicators 
of treatment progress (such as attendance, time in treatment or 
completion of treatment) in order to underline its predictive capacity.
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